Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention

JAMA Cardiol. 2022 Mar 1;7(3):359-360. doi: 10.1001/jamacardio.2021.5399.

Authors

Po-Wei Chen¹, Cheng-Han Lee¹, Ping-Yen Liu¹

Affiliation

¹ Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

PMID: 34985496
DOI: 10.1001/jamacardio.2021.5399

No abstract available

Publication types

Letter

MeSH terms

Female
Humans
Male
Percutaneous Coronary Intervention*
Purinergic P2Y Receptor Antagonists / therapeutic use
Sex Characteristics*

Substances

Purinergic P2Y Receptor Antagonists